Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Quantum Biopharma ( (TSE:QNTM) ).
Quantum BioPharma Ltd. announced on April 3, 2025, that its licensee, Celly Nutrition Corporation, has launched the alcohol detoxification and anti-hangover beverage ‘unbuzzd’ in Puerto Rico. This launch, in partnership with FUSION Distribution Group, marks a significant milestone for the product, which is scientifically proven to accelerate alcohol metabolism and reduce hangover symptoms. The distribution network includes major retailers and aims to make unbuzzd widely available across Puerto Rico and the Caribbean, enhancing Quantum BioPharma’s market presence and potential revenue through royalty agreements.
More about Quantum Biopharma
Quantum BioPharma is a biopharmaceutical company focused on developing innovative solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is engaged in research and development through its subsidiary, Lucid Psycheceuticals Inc., and has a strategic investment portfolio through FSD Strategic Investments Inc.
YTD Price Performance: 97.06%
Average Trading Volume: 2,856,595
Technical Sentiment Signal: Buy
Current Market Cap: $15.83M
Find detailed analytics on QNTM stock on TipRanks’ Stock Analysis page.